Hospira Company Profile (NYSE:HSP)

About Hospira

Hospira logoHospira, Inc. provides injectable pharmaceutical drugs and infusion technologies and it develops, manufactures, distributes and markets biosimilars. The Company's portfolio includes generic acute-care and oncology injectables, biosimilars, and integrated infusion therapy and medication management products. The Company conducts operations across the world and is managed in three segments: the Americas, which include the United States, Canada, and Latin America; Europe, Middle East, and Africa (EMEA), and the Asia Pacific, which includes Asia, Japan, Australia and New Zealand. Its portfolio of products includes Specialty Injectable Pharmaceuticals, which includes generic injectables, injectables and biosimilars, Medication Management and Other Pharmaceuticals. Its portfolio of products is used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drugs - Generic
  • Sub-Industry: Pharmaceuticals
  • Exchange: NYSE
  • Symbol: HSP
  • CUSIP: 44106010
Key Metrics:
  • Previous Close: $0.00
  • 50 Day Moving Average: $90
  • 200 Day Moving Average: $88
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 24.58
  • P/E Growth: 0
  • Market Cap: $N/A
Additional Links:
Companies Related to Hospira:

Analyst Ratings

Consensus Ratings for Hospira (NYSE:HSP) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Hospira (NYSE:HSP)
Show:
DateFirmActionRatingPrice TargetDetails
5/13/2015Deutsche Bank AGReiterated RatingBuy$90.00View Rating Details
2/5/2015Goldman Sachs Group Inc.UpgradeSell -> Neutral$51.00 -> $68.00View Rating Details
11/7/2014JPMorgan Chase & Co.Reiterated RatingNeutral$55.00 -> $56.00View Rating Details
11/7/2014Barclays PLCReiterated RatingEqual Weight$47.00 -> $53.00View Rating Details
11/7/2014Bank of America Corp.Reiterated RatingNeutral$61.00 -> $62.00View Rating Details
11/7/2014Raymond James Financial Inc.UpgradeUnderperform -> Market PerformView Rating Details
9/29/2014CIMBInitiated Coverageadd$2.75View Rating Details
(Data available from 9/25/2014 forward)

Earnings

Earnings History for Hospira (NYSE:HSP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/4/2015        
7/29/2015Q215$0.80$0.85$1.18 billion$1.20 billionViewN/AView Earnings Details
4/28/2015Q115$0.51$0.97$1.08 billion$1.18 billionViewN/AView Earnings Details
2/12/2015Q414$0.42$0.53$1.12 billion$1.13 billionViewListenView Earnings Details
11/6/2014Q314$0.53$0.74$1.08 million$1.15 billionViewListenView Earnings Details
7/30/2014Q214$0.56$0.72$1.05 billion$1.14 billionViewListenView Earnings Details
4/30/2014Q114$0.49$0.60$1.02 billion$1.10 billionViewListenView Earnings Details
2/12/2014Q413$0.50$0.51$1.06 billion$1.10 billionViewListenView Earnings Details
11/6/2013Q313$0.45$0.51$992.20 million$1,000.00 millionViewListenView Earnings Details
7/31/2013Q2 2013$0.51$0.55$1.03 billion$1.03 billionViewListenView Earnings Details
5/1/2013Q1 2013$0.44$0.52$979.33 million$884.00 millionViewListenView Earnings Details
2/13/2013Q4 2012$0.54$0.55$1.04 billion$1.10 billionViewListenView Earnings Details
11/7/2012Q312$0.45$0.47$987.67 million$994.00 millionViewN/AView Earnings Details
8/1/2012$0.49$0.51ViewN/AView Earnings Details
5/1/2012$0.46$0.47ViewN/AView Earnings Details
2/14/2012$0.47$0.51ViewN/AView Earnings Details
10/26/2011$0.95$0.66ViewN/AView Earnings Details
7/27/2011$0.79$0.94ViewN/AView Earnings Details
4/26/2011$0.78$0.93ViewN/AView Earnings Details
2/2/2011$0.93$0.77ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Hospira (NYSE:HSP)
Current Year EPS Consensus Estimate: $3.16 EPS
Next Year EPS Consensus Estimate: $3.66 EPS

Dividends

Dividend History for Hospira (NYSE:HSP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Hospira (NYSE:HSP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/2/2015Matthew R StoberSVPSell21,833$87.49$1,910,169.17View SEC Filing  
2/27/2015Matthew R StoberSVPSell25,338$87.47$2,216,314.86View SEC Filing  
2/17/2015Thomas E WernerCFOSell1,566$87.35$136,790.10View SEC Filing  
1/15/2015Thomas E WernerCFOSell10,000$61.56$615,600.00View SEC Filing  
1/12/2015Matthew R StoberSVPSell2,000$61.80$123,600.00View SEC Filing  
12/15/2014Thomas E WernerCFOSell10,000$60.86$608,600.00View SEC Filing  
12/2/2014Richard J HoffmanCAOSell21,850$60.32$1,317,992.00View SEC Filing  
11/25/2014Marc J YoskowitzSVPSell11,523$59.93$690,573.39View SEC Filing  
11/24/2014Kenneth F MeyersSVPSell46,250$59.66$2,759,275.00View SEC Filing  
11/17/2014Thomas E WernerCFOSell10,000$57.73$577,300.00View SEC Filing  
9/15/2014Thomas E WernerCFOSell10,000$52.74$527,400.00View SEC Filing  
8/15/2014Thomas E WernerCFOSell10,000$55.13$551,300.00View SEC Filing  
7/15/2014Thomas E WernerCFOSell10,000$51.50$515,000.00View SEC Filing  
6/16/2014Thomas E WernerCFOSell10,000$50.82$508,200.00View SEC Filing  
5/21/2014Thomas WernerCFOSell30,000$47.98$1,439,400.00View SEC Filing  
5/16/2014Connie CurranDirectorSell2,000$47.44$94,880.00View SEC Filing  
5/14/2014Barbara BowlesDirectorSell2,000$47.77$95,540.00View SEC Filing  
5/13/2014Richard HoffmanCAOSell15,000$48.07$721,050.00View SEC Filing  
5/12/2014Brian SmithSVPSell40,000$48.00$1,920,000.00View SEC Filing  
3/14/2014Matthew StoberSVPSell19,217$42.28$812,494.76View SEC Filing  
2/26/2014Thomas WernerCFOSell20,000$42.53$850,600.00View SEC Filing  
9/11/2013Richard J HoffmanCAOSell9,850$39.38$387,893.00View SEC Filing  
8/16/2013Matthew StoberSVPSell4,990$40.12$200,198.80View SEC Filing  
6/7/2013Sumant RamachandraSVPSell23,702$35.69$845,924.38View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Hospira (NYSE:HSP)
DateHeadline
cnbc.com logoAs opioid epidemic grows, so do prices of lifesaving overdose drugs (NYSE:HSP)
www.cnbc.com - September 23 at 5:09 PM
finance.yahoo.com logoPfizer Investors Mood Dampened by Second Quarter Earnings (NYSE:HSP)
finance.yahoo.com - August 15 at 5:44 PM
finance.yahoo.com logoPfizer supera previsiones en primer trimestre - Yahoo Finanzas España (NYSE:HSP)
es.finance.yahoo.com - May 4 at 2:11 AM
uk.finance.yahoo.com logoPfizer earnings rise, boosted by Hospira assets - Yahoo Finance UK (NYSE:HSP)
uk.finance.yahoo.com - May 4 at 2:11 AM
uk.finance.yahoo.com logoPfizer earnings rise, boosted by Hospira assets (NYSE:HSP)
uk.finance.yahoo.com - May 3 at 8:33 AM
streetupdates.com logoVolume Leaders of Healthcare Sector: AVEO Pharmaceuticals, (AVEO), AbbVie (ABBV), AEterna Zentaris (AEZS ... - Street Updates (NYSE:HSP)
www.streetupdates.com - March 26 at 12:14 PM
seekingalpha.com logoPfizer: 30%+ Discount With 4% Yield - Seeking Alpha (NYSE:HSP)
seekingalpha.com - March 22 at 2:32 PM
seekingalpha.com logoThe Endless GAAP Vs. Non-GAAP Debate: Instead Focus On Cash Flow - Seeking Alpha (NYSE:HSP)
seekingalpha.com - March 17 at 10:52 AM
prnewswire.com logoHospira Announces U.S. Launch of Generic Bivalirudin for Injection (NYSE:HSP)
www.prnewswire.com - February 27 at 12:24 PM
prnewswire.com logoHospira and Cerner Expand Agreement to Advance Integration of I.V.-EMR Technology (NYSE:HSP)
www.prnewswire.com - February 25 at 11:38 PM
uk.finance.yahoo.com logoPfizer earnings fall on strong dollar, higher expenses (NYSE:HSP)
uk.finance.yahoo.com - February 2 at 10:50 AM
uk.finance.yahoo.com logoNovartis profits jump 73% on asset sales (NYSE:HSP)
uk.finance.yahoo.com - January 27 at 12:02 PM
feeds.reuters.com logoUPDATE 3-Novartis hires Hospira's $90 mln man to save Alcon (NYSE:HSP)
feeds.reuters.com - January 27 at 9:48 AM
bizjournals.com logoWhat Pfizer-Allergan means for manufacturing plant in Rocky Mount (NYSE:HSP)
www.bizjournals.com - November 23 at 12:55 PM
uk.finance.yahoo.com logoPfizer, Allergan weigh blockbuster merger: reports (NYSE:HSP)
uk.finance.yahoo.com - October 29 at 4:54 AM
noodls.com logoPfizer Updates 2015 Financial Guidance Solely to Include Hospira Operations In Financial Results From September 3, 2015 Through Year-End 2015 (NYSE:HSP)
www.noodls.com - September 30 at 8:58 AM
sg.finance.yahoo.com logoIndia-based company doesn't want drug used for executions (NYSE:HSP)
sg.finance.yahoo.com - September 22 at 5:27 PM
sg.finance.yahoo.com logoAPNewsBreak: Arkansas execution plan may use UK firm's drug (NYSE:HSP)
sg.finance.yahoo.com - September 18 at 1:39 PM
moodys.com logoPfizer Inc. -- Moody's assigns A1 to Pfizer's proposed exchange notes (NYSE:HSP)
www.moodys.com - September 3 at 6:05 PM
noodls.com logoPfizer Inc. Commences Exchange Offers for Hospira Notes (NYSE:HSP)
www.noodls.com - September 3 at 5:35 PM
bloomberg.com logoEx-Hospira CEO Trades Shares for $91 Million Cash in Pfizer Deal (NYSE:HSP)
www.bloomberg.com - September 3 at 4:33 PM
biz.yahoo.com logoHOSPIRA INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposit (NYSE:HSP)
biz.yahoo.com - September 3 at 12:38 PM
noodls.com logoPfizer Completes Acquisition of Hospira (NYSE:HSP)
www.noodls.com - September 3 at 9:35 AM
finance.yahoo.com logoTwo steady stocks among S&P 500 (NYSE:HSP)
finance.yahoo.com - September 2 at 7:03 AM
finance.yahoo.com logoS&P 500 picks up ATVI and UAL (NYSE:HSP)
finance.yahoo.com - August 28 at 9:00 AM
noodls.com logoHospira Announces First Installation of Plum 360™ Infusion System With Hospira MedNet™ (NYSE:HSP)
www.noodls.com - August 27 at 10:54 AM
noodls.com logoExpert committee BACKS Hospira’s InflectraTM (NYSE:HSP)
www.noodls.com - August 21 at 2:56 AM
noodls.com logoCharleston Area Medical Center Integrates Smart Pump Technology to Advance Patient Safety (NYSE:HSP)
www.noodls.com - August 20 at 11:16 AM
noodls.com logoTGA Approves First Mab Biosimilar (NYSE:HSP)
www.noodls.com - August 20 at 5:22 AM

Social

Hospira (NYSE:HSP) Chart for Sunday, September, 25, 2016


Last Updated on 9/25/2016 by MarketBeat.com Staff